Ferroptosis

Ferroptosis-IN-4 (compound 6k), an inhibitor of ferroptosis, exhibits an EC50 of 20 μM and lacks significant cytotoxicity. It demonstrates a protective role in glycerol-induced RM-AKI mice by alleviating kidney dysfunction [1].

JST-TfR09 (PPMX-T003) is a human monoclonal antibody (mAb) targeting CD71. It reduces ferritin levels in ATLL cell lines to induce ferroptosis, increases the production of ferrous ions and reactive oxygen species (ROS), and induces lipid peroxidation through malondialdehyde. JST-TfR09 is applicable in leukemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control.

Roxadustat-d5 is a reference standard for GC/LC-MS quantification of a HIF-PH inhibitor, distinct from other dioxygenases.

Deferitazole (FBS 0701) is a novel and orally active, selective and high affinity iron chelator.

FA16 is a selective, metabolically stable ferroptosis inducer with an IC50 value of 1.26 μM.FA16 is a derivative of 2-(trifluoromethyl)benzimidazole.FA16

Utreloxastat (PTC857) is a novel 15-lipoxygenase inhibitor that can be used to study amyotrophic lateral sclerosis .

BCP-T.A is an iron death inducer that acts by binding to GPX4.

HBED (CHELII) is an iron chelator and can be used in research on the treatment of chronic iron overload and acute iron poisoning.

Erastin2 is an iron death inducer that induces cell death by binding to the lipophilic free radical trapping antioxidant ferrostatin-1 or the iron chelator DFO.

Ogremorphin (GPR68-IN-1) is a potent inhibitor of GPR68, exhibiting an EC50 of 170 nM.it is utilized in the study of autoimmune chronic inflammatory diseases [1

viFSP1, a species-independent FSP1 inhibitor, effectively induces ferroptosis in FSP1-dependent cells by targeting the highly conserved NAD(P)H binding pocket of FSP1, directly inhibiting its activity. This action results in lipid peroxidation and exhibits anticancer activity [1].

Docebenone is a selective and orally active inhibitor of 5-LO.

CP-24879 HCl, a Δ5D/Δ6D dual-inhibitor, reduces liver lipid buildup and inflammation.

Cerivastatin is an HMG-CoA reductase inhibitor with anticancer and lipid-lowering effects and can be used to study primary hyperlipidemia.

Ferroptosisinducer-5 (compound 20a) is an inducer of ferroptosis.

FerroLOXIN-1 is a potent inhibitor of 15LOX-2, selectively blocking the production of ferroptosis-promoting HOO-ETE-PE and preventing RSL3-induced ferroptosis (ferroptosis). It interacts closely and specifically with 15LOX-2, particularly engaging with Y154, N155, and W158.

DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent and specific glutamylcysteine synthetase biosynthesis inhibitor

Ferroptosis-IN-6 is an efficient ferroptosis inhibitor, protecting cells from cell death induced by ferroptosis inducers, and inhibiting STY-BODIPY oxidation.

Ferroptosis-IN-21 is an inhibitor of ferroptosis that combats renal ischemia-reperfusion injury by directly scavenging peroxy free radicals to prevent cell death. It demonstrates broad-spectrum, nanomolar-level inhibitory potency against various ferroptosis inducers in renal tubular epithelial cells and effectively suppresses the accumulation of lipid reactive oxygen species (ROS). Additionally, Ferroptosis-IN-21 significantly alleviates renal ischemia-reperfusion injury in mice, as evidenced by improved histological damage and functional impairment, reduced expression of inflammatory cytokines, and decreased levels of lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-21 is a potential candidate in research for developing ferroptosis-targeted therapeutics.

GPX4-IN-3 is a selective GPX4 inhibitor inducing ferroptosis (71.7% inhibition at 1 μM).